PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (390)	1/30/2002 5:20:26 AM
From: mopgcw	Read Replies (1) of 539

Proteome Sciences : NvCJD, BSE Detection Patent DOW JONES NEWSWIRES LONDON -- Proteome Sciences plc, the AIM listed proteomics and modification of gene expression company, said that its patent portfolio in TSE assays has been strengthened by the grant of an Australian patent. The patent is for the detection of prion proteins using human or animal blood samples to separate mononuclear cells for the detection of abnormal prions in humans for nvCJD and for BSE in cattle. The tests can detect TSEs in live humans/animals and not only from pathological material. This patent was originally filed in November 1996 and its prosecution is proceeding in other countries. Proteome Sciences has filed a number of other patents exploiting its proteomics technology to assay for the presence of TSE in the blood of various species. In controlled studies using human blood from CJD/nvCJD patients compared with relevant control samples, Proteome Sciences has identified changes in protein expression and produced assays which provide high sensitivity, specificity and predictive accuracy. Studies to further validate these findings are in progress. The same assays have yielded similar results in blood samples from BSE infected cattle and studies using samples from scrapie positive sheep are in preparation. It is expected that the complementarity of these two series of assays will be of value in the early diagnosis of TSE in the three major species of interest and in particular for nvCJD, BSE, scrapie and for blood transfusion screening. Proteome Sciences is actively engaged to establish development and commercialisation partnerships to accelerate its blood markers programmes and to exploit the commercial potential for TSE in human and animal prion disease applications

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next